Mechanism of Alzheimer Amyloid β-Protein Precursor Localization to Membrane Lipid Rafts by Saito, Yuhki et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Mechanism of Alzheimer Amyloid β-Protein
Precursor Localization to Membrane Lipid Rafts
Yuhki Saito, Takahide Matsushima and
Toshiharu Suzuki
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54096
1. Introduction
Alzheimer’s disease (AD) is a group of common neurodegenerative diseases associated with
progressive dementia with aging. The principal pathological hallmarks of AD are senile pla‐
ques and neurofibrillary tangles in the brain, which are found at significantly higher fre‐
quencies in AD patients than age-matched healthy (non-AD) subjects [1]. Senile plaques
consist mainly of 39–43 amino-acid amyloid-β (Aβ) peptide, which is generated by sequen‐
tial proteolytic processing of amyloid β-protein precursor (APP) (Figure 1) [2]. Common Aβ
species generated in the human and murine brain are Aβ40 and Aβ42. Mutations in APP
and Presenilin, which have been identified as familial AD-causative genes, result in in‐
creased Aβ production and/or an increased ratio of neurotoxic Aβ42.
Aβ is generated by sequential processing of APP with β- and γ-secretase, the catalytic unit
of which is presenilin. Findings reported during the late 1980s and early 1990s led to the
proposal of the “Aβ cascade hypothesis” of AD onset, which states that Aβ generation is a
primary cause of AD [3]. Several lines of evidence indicate that the amyloidogenic process‐
ing of APP, including Aβ generation, occurs in membrane microdomains termed lipid rafts
[4]. However, the molecular mechanisms underlying APP translocation to lipid rafts remain
unclear. In this chapter, regulatory mechanisms for lipid raft translocation of APP and APP
C-terminal fragments (APP CTFs) generated primarily by the cleavage of APP are described.
Membrane lipid rafts are known as sites of amyloidogenic processing of APP and enriched
with active β-secretase, while non-amyloidogenic cleavage of APP by α-secretase is per‐
formed outside lipid rafts. Neural adaptor protein X11-like (X11L) regulates the transloca‐
tion of mature APP (mAPP), which is the N- and O-glycosylated form and real substrate of
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secretases in the late protein secretory pathway, to lipid rafts. APP bound to X11L preferen‐
tially localizes to sites outside of lipid rafts and escapes from active β-secretase [5]. Dissocia‐
tion of the APP-X11L complex leads to APP entry into lipid rafts, suggesting that
dysfunction of X11L in its interaction with APP may recruit more APP to lipid rafts and in‐
crease the generation of Aβ [5].
Figure 1. The schema of APP metabolism and post-translational modification of APP. APP is subjected to N-glyco‐
sylation at ER to form imAPP followed by O-glycosylation at the medial-/trans-Golgi apparatus to form mAPP. Residue
Thr668 of mAPP is specifically phosphorylated in brain. mAPP is cleaved in sequential proteolytic events mediated by
β-secretase or α-site APP cleaving enzyme, and the γ-secretase complex. β-secretase primarily cleaves APP in the lumi‐
nal domain to generate sAPPβ and CTFβ (C99 and C89). C99 contains an intact Aβ sequence. γ-secretase complex me‐
diates the cleavage of CTFβ at ε, ζ, and γ-sites to generate Aβ and AICD peptides. α-site APP cleaving enzyme
generates sAPPα and CTFα (C83). CTFα cleavage by γ-secretase complex then generates p3 peptide and AICD.
In contrast to APP, APP CTF translocation to lipid rafts seems to involve another regulatory
system that also includes active γ-secretase to cleave APP CTFs. The translocation of CTFs to
lipid rafts is regulated by APP phosphorylation. The cytoplasmic region of APP is well
known to demonstrate neuron-specific phosphorylation at Thr668 (numbering for the
APP695 isoform). However, the maximum phosphorylation level of APP is 10–20% in the
brain, and its physiological function is not clear [6].
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A recent study found that the phosphorylation level of APP CTFs was much higher than
that of full-length APP, and phosphorylated CTFs (pCTFs), but not nonphosphorylated
CTFs (nCTFs), were preferentially located outside of detergent-resistant, lipid raft-like mem‐
brane microdomains, indicating that Thr668 phosphorylation appears to function on the
APP CTF rather than full-length APP [7]. Recent analysis revealed that pCTFs are relatively
movable within the membrane as integral membrane proteins, while nCTFs are susceptible
to being anchored to a lipid raft by direct binding of the C-terminal tail to membrane lipids.
Once in lipid rafts, nCTFs can be preferentially captured and cleaved by γ-secretase. Inter‐
estingly, phosphorylation levels of amyloidogenic CTFβ were significantly decreased in
aged brain [7]. Two molecular mechanisms of APP and APP CTF translocation to ripid rafts
are described in the following section.
2. Metabolism and post-translational modification of APP
APP,  which  is  a  type  I  membrane  protein,  is  subjected to  N-glycosylation  at  the  endo‐
plasmic  reticulum (ER)  to  form immature  APP (imAPP) followed by O-glycosylation at
the medial-/trans-Golgi  apparatus to form mature APP (mAPP) (Figure 1).  mAPP is  then
transported  through  the  trans-Golgi  network  to  the  plasma  membrane,  where  it  enters
the late secretory pathway and is metabolized by either amyloidogenic or amyloidolytic
(non-amyloiodgenic) processing [6,  8].  In the amyloidogenic pathway, APP is cleaved in
sequential  proteolytic  events  mediated by β-secretase  (β-site  APP cleaving enzyme 1  or
BACE1) and the γ-secretase complex comprised of four core subunits, presenilins (PS1 or
PS2),  anterior pharynx defective 1 (APH-1),  presenilin enhancer 2 (PEN2),  and nicastrin.
β-secretase  primarily  cleaves  APP  in  the  luminal  domain  to  generate  soluble  APPβ
(sAPPβ)  and  membrane-associated  APP  carboxyl  terminal  fragments  (CTFβ/C99  and
CTFβ′/C89). C99 contains an intact Aβ sequence (Figure 1). γ-secretase complex mediates
the cleavage of  CTFβ at  ε,  ζ,  and γ-sites  to  generate  Aβ and APP intracellular  domain
(AICD) peptides.  Non-amyloidogenic cleavage of  APP is  mediated by α-site  APP cleav‐
ing  enzyme  (α-secretase,  including  ADAM9,  ADAM10,  and  ADAM17)  to  generate
sAPPα  and  CTFα  (C83),  which  contains  only  the  carboxyl  half  of  Aβ  peptide.  CTFα
cleavage by γ-secretase complex then generates p3 peptide and AICD.
Residue Thr668 of the APP cytoplasmic region is located within the 667-VTPEER-672 motif
and is phosphorylated (number corresponding to the APP695 isoform) in the late secretory
pathway in neurons. Protein kinases such as GSK3β (glycogen synthase kinase-3β), CDK5
(cyclin-dependent kinase-5), CDK1/CDC2, and JNK (c-Jun N-terminal kinase) are thought to
mediate this phosphorylation of APP [6]. APP CTFs are also phosphorylated at Thr668 and
detected as phosphopeptide pC99, pC89, and pC83 by western blot analysis using a phos‐
phorylation-state-specific anti-APP Thr668 antibody or pAPP antibody (Figure 2A). Typical
APP CTF species in the brain appear as five bands: pC99, nC99, pC89, a mixture of nC89
plus pC83, and nC83. Treatment of CTFs with phosphatase is effective for the identification
of the respective species. Levels of the phosphorylated CTFβ species pC99 and pC89 were
significantly higher than those of their nonphosphorylated forms, nC99 and nC89, while
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phosphorylated CTFα, pC83, demonstrated a trend toward decreased levels in comparison
to nonphosphorylated CTFα, nC83 (Figure 2B). The relative ratio of total phosphorylated
CTFs was equivalent to that of nonphosphorylated CTFs (Figure 2C), although phosphory‐
lated CTFβ and CTFβ' were predominant compared to their nonphosphorylated forms.
These observations indicate that pCTFs and nCTFs are present at equal levels in the brain as
potential substrates for γ-secretase.
Figure 2. Level of CTF species in brain membrane fractions. (A) CTF species in brain membrane preparations. (B) and
(C) Levels of CTF species in brain membrane preparations. Levels of the phosphorylated CTFβ species (pC99 and pC89)
were significantly higher than those of their nonphosphorylated forms, nC99 and nC89.
The 667-VTPEER-672 motif, including the phosphorable amino acid Thr668, forms a type I
β-turn and N-terminal helix-capping box structure to stabilize its C-terminal helix structure
[9]. Therefore, phosphorylation of Thr668 induces significant conformational changes in the
cytoplasmic region of APP (Figure 3) that affect its interaction with FE65, a neuronal adaptor
protein [10]. The usual procedure to explore the function of a protein phosphorylation site is
to mimic the phosphorylation state by amino acid substitutions of Asp or Glu for the appro‐
priate Thr and Ser residues. However, this strategy may not be suitable in the case of APP
phosphorylation, as the substitution of Asp for Thr668 did not alter the carboxyl terminal
helix state as remarkably as phosphorylation of Thr668 (Figure 3A). By contrast, substitution
of Thr668 with Ala668 in APP has been found to mimic effectively the nonphosphorylated
state in the helix structure of the APP cytoplasmic domain. Figure 3B presents a schematic
illustration of the Thr668-dependent conformational changes. Thr668Ala mutation mimics
the nonphosphorylated state of APP, but Thr668Asp mutation did not completely mimic the
phosphorylation structure of APP. Therefore, to reveal the role of APP phosphorylation at
Thr668, careful analysis for the phosphorylation state of both APP and the APP metabolic
fragments in the brain are described here.
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Figure 3. Circular dichroism (CD) spectra of APP cytoplasmic peptides (A) and schematic of changes to the APP cyto‐
plasmic domain dependent on Thr668 residue modification (B). The substitution of Asp for Thr668 did not alter the
carboxyl terminal helix state as remarkably as phosphorylation of Thr668. By contrast, substitution of Thr668 with
Ala668 in APP has been found to mimic effectively the nonphosphorylated state in the helix structure of the APP cyto‐
plasmic domain.
3. Lipid rafts and Alzheimer’s disease
Dynamic and highly ordered membrane microdomains, termed lipid rafts, are rich in cho‐
lesterol and sphingolipids such as seramide, gangliosides, glycerophospholipids, and ster‐
ols. The average diameter of lipid rafts has been estimated at 50 nm. However, several
classes of lipid rafts that vary in size and duration can exist in a cell [11]. Lipid rafts are
formed in the Golgi and transported to the plasma membrane [12], where they serve as plat‐
forms for cell signaling, pathogen entry, cell adhesion, and protein sorting. Lipid rafts are
biochemically defined as the detergent-resistant membrane (DRM) fraction [12]. Aβ genera‐
tion and aggregation occur in lipid rafts, suggesting that lipid rafts play an important role in
APP processing and subsequent AD pathogenesis. A growing body of evidence indicates
that active β- and γ-secretases are located in membrane microdomains [13-15]. S-Palmitoyla‐
tion of BACE1 at residues Cys474/478/482/485 is essential for the localization of BACE1 to
lipid rafts [13,14]. S-Palmitoylation of nicastrin at Cys689 and of APH1 at Cys182 and
Cys245 contributed to their stability and the lipid raft association of these nascent subunits,
but did not affect the lipid raft localization of PS1 and PEN2 or the assembly of γ-secretase
complex [15]. Taken together, lipid raft localization of secretases involved in amyloidogenic
APP cleavage is regulated by their post-translational modification. However, the factors that
determine lipid raft localization of APP remain unclear.
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4. X11 protein regulation of APP localization to lipid rafts
X11 family proteins (X11s), consisting of X11/X11α/Mint1, X11L/X11β/Mint2, and X11L2/
X11γ/Mint3, are encoded by separate genes on human chromosomes 9, 15, and 19 and
mouse chromosomes 19, 7, and 10, respectively. X11s contain an evolutionarily conserved
central phosphotyrosine binding/interaction (PTB/PI) domain and two C-terminal PDZ do‐
mains [16]. The PTB/PI and PDZ domains are well-characterized protein-protein interaction
domains, and X11 proteins interact with various types of proteins, including APP, alcadein,
apoER2, munc18, KIF17, kalirin, hyperpolarization-activated cyclic nucleotide-gated (HCN)
channel, and Arfs, through their PTB/PI and PDZ domains. Interaction of X11L with APP
can stabilize APP metabolism and intracellular trafficking, which induce the suppression of
Aβ generation [16-18]. Metabolic analysis of APP in X11 and/or X11L knockout mice con‐
firmed that X11s modulated APP metabolism and suppressed Aβ generation as an endophe‐
notype in vivo [5, 19, 20]. X11 or X11L transgenic mice crossed to commonly used AD model
mice (APPswe transgenic mice) demonstrated reduced amyloid deposition along with de‐
creased levels of Aβ40 and Aβ42 in the brain compared to APPswe transgenic mice [21, 22].
The molecular mechanisms underlying the suppression of APP amyloidogenic metabolism by
X11 and X11L have been addressed in a recent analysis. In the brains of mice lacking X11 and/or
X11L, levels of CTFβ and Aβ were increased relative to wild-type animals (Figure 4) [5].
Figure 4. Quantification of APP CTFs in the hippocampus of wild-type, X11-deficient, X11L-deficient, and X11/X11L
doubly deficient mice. Levels of CTFβ and Aβ were increased in X11s deficient mice, indicating that amyloidogenic me‐
tabolism of APP was enhanced in X11s deficient mice.
The absence of X11s resulted in more APP and APP CTF translocation to DRMs and en‐
hanced colocalization of APP or APP CTFs with BACE1 in DRMs but not in non-DRMs (Fig‐
ure 5A and B) [5]. Interestingly, X11s were recovered in membrane fractions, and they
largely localized to non-DRMs but not DRMs (Figure 5C), indicating that APP can associate
exclusively with X11s outside of DRMs to prevent APP translocation to lipid rafts, where
amyloidogenic metabolism of APP occurs (Figure 6).
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Figure 5. Quantification of APP, APP CTFs, BACE, and PS1 in (A) DRM and (B) non-DRM fractions from wild-type, X11-
deficient, X11L-deficient, and X11/X11L doubly deficient mouse cortex. Higher levels of mAPP and CTFβ were recov‐
ered in DRM of the X11L-deficient and the X11/X11L doubly deficient mouse brain. (C) Localization of membrane-
attached X11 proteins to DRM and non-DRM fractions. X11s were recovered in membrane fractions, and they largely
localized to non-DRMs but not DRMs.
The Dysfunction of X11s in aged neurons may thus contribute to sporadic AD etiology. The
dysfunction of X11s could lead to a weakening of the association between X11s and APP,
resulting in greater translocation of APP to DRMs. Alteration in the lipid composition of
membranes may enlarge lipid raft areas or increase the number of lipid rafts, which could
also enhance APP translocation to DRMs. These qualitative alterations in X11s and/or lipid
metabolism could result in increased β-cleavage of APP even if β-secretase itself is not enzy‐
mopathic.
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Figure 6. Possible role of X11 proteins in regulating the DRM association and β-site cleavage of APP. X11s asso‐
ciate with APP outside of DRMs and prevent translocation of APP into DRM. When X11L dissociates from APP, the APP
translocates into DRMs, and that fraction of APP molecules is cleaved by BACE which is active in DRM (upper panel). In
the absence of X11s, APP molecules are not anchored outside of DRMs, and more APP translocates into DRMs, result‐
ing in increased β-site cleavage of APP (lower panel). The arrows indicate translocation direction of APP.
5. Regulation of APP CTF translocation to lipid rafts by Thr668
phosphorylation
Because similar amounts of nCTFs and pCTFs were found in mouse brain (Figure 2C), gen‐
eration of similar levels of the APP intracellular cytoplasmic domain fragments, nonphos‐
phorylated AICD (nAICD) and phosphorylated AICD (pAICD), is expected if γ-secretase
cleaves nCTFs and pCTFs equivalently. However, membrane prepared from mouse brain
generated higher levels of nAICD than pAICD in an in vitro γ-secretase assay (Figure 7A).
Incubation of membrane preparations demonstrated a time-dependent, nearly linear in‐
crease in the generation of nAICD and pAICD during the 0–2 h time period, and the reac‐
tion essentially reached a plateau in the 2–4 h period (Figure 7B and C). Dephosphorylation
and degradation of pAICD did not occur in this assay. Importantly, the ratio of pAICD to
AICD generation was constant throughout the incubation time (1–4 h) with the relative ratio
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(amount of pAICD/amount of nAICD) measuring 0.35 ± 0.10 at the 2 h point (Figure 7D).
Taken together, these in vitro analyses indicate that both phosphorylated and nonphos‐
phorylated CTFs are kinetically equivalent as a substrate for γ-secretase, but the results also
show that the generation of pAICD was significantly lower when compared to that of
nAICD. These observations suggest that pCTFs are located at a distance from active γ-secre‐
tase in the membrane, while nCTFs are positioned nearer to the active enzyme.
Figure 7. In vitro kinetic analysis of phosphorylated and nonphosphorylated CTF cleavage by γ-secretase. (A) in vitro γ-
secretase assay with membrane preparations from wild-type mouse brain. (B) and (C) kinetic analysis of AICD generat‐
ed by incubation of membrane preparations. (D) the production ratio of pAICD to nAICD (pAICD/nAICD) at the
indicated times are shown. Both phosphorylated and nonphosphorylated CTFs are kinetically equivalent as a substrate
for γ-secretase, but the results also show that the generation of pAICD was significantly lower when compared to that
of nAICD.
Thr668 phosphorylation could regulate APP CTF translocation to the lipid raft microdo‐
main. To examine this hypothesis, γ-secretase-enriched lipid raft-like membrane microdo‐
mains were prepared as DRMs using CHAPSO. Application of CHAPSO is preferable for
the isolation of DRMs, including active γ-secretase complexes, compared to procedures us‐
ing other detergents such as Triton X-100 [23, 24]. Components of the active γ-secretase com‐
plex, both PS1 N- and C-terminal fragments and PEN2, were predominantly recovered in
the DRM fraction along with a small amount of APP CTFs (~20% measured) [7]. Phosphory‐
lation levels of APP CTFs in the DRM and non-DRM fractions were examined, and the re‐
spective nCTFs and pCTFs were compared as a relative ratio in which pC99 in the DRM was
set to 1.0 (Figure 8).
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Figure 8. Quantification of pCTFs and nCTFs in DRM and non-DRM fractions. (A) Identification of APP CTFs in DRM
and non-DRM fractions. (B) CTFs levels in DRM and non-DRM fractions. Significantly higher levels of the phosphorylat‐
ed species pC99, pC89, and pC83 were found in the non-DRM fractions.
Significantly higher levels of the phosphorylated species pC99, pC89, and pC83 were found
in the non-DRM fractions compared to the DRM fractions. Additionally, the phosphoryla‐
tion level of total APP CTFs in DRM was significantly lower than that in non-DRM. These
results indicate that phosphorylated CTFs are preferentially localized outside of the DRM/
lipid raft-like membrane microdomain and thus prevented from cleavage by γ-secretase.
How does phosphorylation of Thr668 regulate the localization of APP CTFs between DRM
and non-DRM? A recent structural analysis revealed that the cytoplasmic domain tail of
APP can interact with membrane lipids [25]. Since phosphorylation of APP at Thr668 indu‐
ces a significant change in its cytoplasmic domain conformation (Figure 2) [9, 10, 26], phos‐
phorylation of the APP cytoplasmic domain at Thr668 can influence the association of the
APP cytoplasmic tail with membrane lipids.
Liposomes prepared with endogenous lipids from the membrane fractions of mouse brain
have been used as a model for neural membranes [27]. Synthetic cytoplasmic APP 648–695 pep‐
tide with (pC47) or without (nC47) a phosphate group at residue Thr668 was incubated with
the liposomes, and the liposome-bound peptides were recovered and analyzed by immuno‐
blotting. Notably, nonphosphorylated APP cytoplasmic peptide (nC47) bound strongly to the
liposomes, while phosphorylated peptide (pC47) demonstrated no detectable association (Fig‐
ure 9A) [7]. This trend was also confirmed by examining the AICD, which lacks the transmem‐
brane domain due to ε-cleavage by γ-secretase [28, 29]. Most nAICD was recovered in the brain
membrane fraction (~75%) rather than in the soluble cytoplasmic fraction (~25%), while com‐
paratively more pAICD was found in the cytoplasmic fraction (~45%) (Figure 9B).
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Figure 9. Liposome-binding ability of APP cytoplasmic domain and ist localization in mouse brain. (A) The binding
ability of the phosphorylated APP cytoplasmic domain peptide with liposomes composed of lipids from mouse brain
membranes. (B) distribution of AICD endogenously generated in mouse brain. Nonphosphorylated nC47 and AICD
bound strongly to the liposome and membrane fraction.
Therefore, the nonphosphorylated forms of APP CTFs and AICD tend to bind membrane
lipids, mediated by their C-termini, and phosphorylation of APP CTFs and AICD at Thr668
functions to prevent direct membrane association, apparently by changing the conformation
of their cytoplasmic regions. In addition to these observations, pCTFβ levels were signifi‐
cantly decreased with age in cynomolgus monkey brains [7], indicating that the preservation
of APP CTF phosphorylation levels correlates with the suppression of γ-cleavage.
To conclude this section, first, almost equal amounts of pCTFs and nCTFs are present in
mouse brain, while lower amounts of pAICD are generated compared to nAICD. Second,
both pAICD and nAICD are kinetically equivalent substrates for γ-secretase. These observa‐
tions suggest that pCTFs are sequestered away from the membrane region where γ-secre‐
tase is active (DRM/lipid raft-like membrane microdomain) [15], and that pCTFs are located
outside of the DRM/lipid raft-like membrane microdomain due to a change in the conforma‐
tion of their cytoplasmic tail, to which the membrane lipids bind. Thus, the pCTFs can
quickly disperse from the DRM/lipid raft-like membrane microdomain with their increased
mobility in the membrane (Figure 10).
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Figure 10. Possible role of APP CTF phosphorylation at Thr668 in regulating its fluidity within the membrane and its
cleavage by γ-secretase.
6. Conclusions
X11L abundantly present in non-DRM traps APP outside of the DRM and prevents contact
between APP and the β-secretases located within the DRM. Phosphorylation of APP at
Thr668 induces conformational changes to the APP cytoplasmic domain and reduces the af‐
finity of the APP C terminal to lipids. This change alters APP CTF fluidity and decreases the
probability of APP CTF presence in lipid rafts, in which contact between APP CTFs and γ-
secretase occurs. In conclusion, translocation of APP and APP CTFs to lipid rafts is regulat‐
ed by neuronal adaptor protein X11L and Thr668 phosphorylation of APP CTFs.
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Abbrevations
ADAM: a disintegrin and metalloprotease domain, APH-1: anterior pharynx defective 1,
AICD: APP intracellular domain, APP: amyloid precursor protein, APP CTFs: APP C-termi‐
nal fragments, BACE1: β-site APP cleaving enzyme 1/β-secretase, CDK5: cyclin-dependent
kinase-5, CD spectra: Circular dichroism spectra, DRM: detergent-resistant membrane,
GSK3:βglycogen synthase kinase-3β, JNK: c-Jun N-terminal kinase, imAPP: immature APP,
mAPP: mature APP, pAICD; nAICD; nonphosphorylated AICD, nCTFs; nonphosphorylated
CTFs, phosphorylated AICD, pCTFs; phosphorylated CTFs, PS: presenilins, PEN2; preseni‐
lin enhancer 2, PTB/PI domain; phosphotyrosine binding/interaction domain; sAPP; soluble
APP, X11L; X11-like.
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